Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.

van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, Schwartz K, Laborde N, Soto-Torres L.

PLoS One. 2014 Feb 21;9(2):e89118. doi: 10.1371/journal.pone.0089118. eCollection 2014.

2.

Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.

van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET; VOICE-C Study Team.

J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19146. doi: 10.7448/IAS.17.3.19146. eCollection 2014.

3.

Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".

Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, Laborde N, Soto-Torres L.

AIDS Behav. 2015 May;19(5):784-93. doi: 10.1007/s10461-014-0950-5.

4.

Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.

Luecke EH, Cheng H, Woeber K, Nakyanzi T, Mudekunye-Mahaka IC, van der Straten A; MTN-003D Study Team.

J Int AIDS Soc. 2016 May 30;19(1):20875. doi: 10.7448/IAS.19.1.20875. eCollection 2016.

5.

Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa.

Magazi B, Stadler J, Delany-Moretlwe S, Montgomery E, Mathebula F, Hartmann M, van der Straten A.

BMC Womens Health. 2014 Jul 28;14:88. doi: 10.1186/1472-6874-14-88.

6.

Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.

Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM.

AIDS Behav. 2017 May;21(5):1361-1375. doi: 10.1007/s10461-016-1458-y.

7.

Sharing of Investigational Drug Among Participants in the Voice Trial.

Moodley J, Naidoo S, Moodley J, Ramjee G.

AIDS Behav. 2016 Nov;20(11):2709-2714. Erratum in: AIDS Behav. 2016 Nov;20(11):2715-2716.

8.

Hidden harms: women's narratives of intimate partner violence in a microbicide trial, South Africa.

Stadler J, Delany-Moretlwe S, Palanee T, Rees H.

Soc Sci Med. 2014 Jun;110:49-55. doi: 10.1016/j.socscimed.2014.03.021. Epub 2014 Mar 22.

PMID:
24721447
9.

Negotiating the use of female-initiated HIV prevention methods in a context of gender-based violence: the narrative of rape.

Hartmann M, Montgomery E, Stadler J, Laborde N, Magazi B, Mathebula F, van der Straten A.

Cult Health Sex. 2016;18(6):611-24. doi: 10.1080/13691058.2015.1101786. Epub 2015 Nov 9.

10.

Women's perceptions and experiences of HIV prevention trials in Soweto, South Africa.

Stadler JJ, Delany S, Mntambo M.

Soc Sci Med. 2008 Jan;66(1):189-200. Epub 2007 Sep 29.

PMID:
17904718
11.

Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.

Montgomery ET, Mensch B, Musara P, Hartmann M, Woeber K, Etima J, van der Straten A.

AIDS Behav. 2017 Feb;21(2):481-491. doi: 10.1007/s10461-016-1609-1.

PMID:
27858268
12.

Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.

Minnis AM, van der Straten A, Salee P, Hendrix CW.

AIDS Behav. 2016 Jul;20(7):1541-8. doi: 10.1007/s10461-015-1081-3.

13.

Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

Mensch BS, Brown ER, Liu K, Marrazzo J, Chirenje ZM, Gomez K, Piper J, Patterson K, van der Straten A.

AIDS Behav. 2016 Nov;20(11):2654-2661.

14.

Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.

Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, Malamatsho F, Odhiambo J, Skhosana J, Van Damme L.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):452-61. doi: 10.1097/QAI.0000000000000880.

PMID:
26536315
15.

The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.

Mack N, Evens EM, Tolley EE, Brelsford K, Mackenzie C, Milford C, Smit JA, Kimani J.

J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19157. doi: 10.7448/IAS.17.3.19157. eCollection 2014.

16.

User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa.

Sahin-Hodoglugil NN, Montgomery E, Kacanek D, Morar N, Mtetwa S, Nkala B, Philip J, Ramjee G, Cheng H, van der Straten A, The Mira Team.

AIDS Care. 2011 Aug;23(8):1026-34. doi: 10.1080/09540121.2010.543879.

PMID:
21480005
17.

Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique.

Falcao J, Zerbe A, Lahuerta M, Baggaley R, Ahoua L, DiMattei P, Morales F, Ramiro I, El-Sadr WM.

AIDS Patient Care STDS. 2017 Dec;31(12):528-534. doi: 10.1089/apc.2017.0179.

PMID:
29211515
18.

Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.

van der Straten A, Mayo A, Brown ER, Amico KR, Cheng H, Laborde N, Marrazzo J, Torjesen K.

AIDS Behav. 2015 May;19(5):770-83. doi: 10.1007/s10461-014-0945-2.

19.

Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.

Govender EM, Mansoor LE, Abdool Karim Q.

AIDS Care. 2017 Jun;29(6):734-740. doi: 10.1080/09540121.2016.1248349. Epub 2016 Nov 1.

PMID:
27799005
20.

Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation.

Chakrapani V, Newman PA, Shunmugam M, Mengle S, Varghese J, Nelson R, Bharat S.

AIDS Patient Care STDS. 2015 Oct;29(10):569-77. doi: 10.1089/apc.2015.0143. Epub 2015 Sep 8.

PMID:
26348459

Supplemental Content

Support Center